In the present study, we found that CD34+/CD38− MPN NSC display numerous 'therapeutic' targets, including CD33, CD44, CD47, CD97, CD99, CD117, CD123, CD133, CD184, and CD274 (PD‐L1) independent of the type of MPN or molecular driver lesion. The gene discussed is CD33; the disease is myeloproliferative disorder.